Effect of neoadjuvant chemotherapy on stromal CD10 antigens in breast cancer - A preliminary study

Indian Journal of Cancer

Volumn 50, Issue 1, 2013, Pages 46-51

  Thomas, S ^a   Babu, R J ^a   Agarwal, K ^a   Puri, V ^a   Jain, M ^a   Andley, M ^a   Tudu, S K ^a  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

Author keywords

Adjuvant chemotherapy; Anthracyclines; Breast cancer; CD10 antigen

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL;

ADULT; ANTIGEN EXPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PROTEIN EXPRESSION; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; ANTHRACYCLINES; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEPRILYSIN; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; STROMAL CELLS;

EID: 84878843354     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.112299     Document Type: Conference Paper

References (18)

1. Gianni L, Valagussa P, Zambetti M, Moliterni A, Capri G, Bonadonna G. Adjuvant and neoadjuvant treatment of breast cancer. Semin Oncol 2001;28:13-29.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of HER2/neu oncogene. Science 1987;235:177-82.
3. Tacca O, Penault-Llorca F, Abrial C, Mouret-Reynier MA, Raoelfils I, Durando X, et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy. Oncologist 2007;12:636-43.
4. Quddus RM, Sung JC, Zhang C, Pasqueriello T, Eklund M, Steinhoff MM. HER2/neu expression in locally advanced breast carcinomas: Pre-and post-neoadjuvant chemotherapy. Breast Cancer 2005;12:294-8.
5. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004;17:646-52.
6. Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal CD10 expression in invasive breast carcinoma; a new predictor of clinical outcome. Virchows Arch 2002;440:589-93.
7. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 2007;20:84-9.
8. Pan C, Cardarelli PM, Nieder MH, Pickford LB, Gangwar S, King DJ, et al. CD10 is a key enzyme involved in the activation of tumoractivated peptide prodrug CPI-0004Na and novel analogues: Implications for the design of novel peptide prodrugs for therapy of CD10+ tumours. Cancer Res 2003;63:5526-31.
9. Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, et al.; GEICAM Group (Spanish Breast Cancer Research Group), Spain. Doxorubicin in combination with fluorouracil and cyclophosphamide versus methotrexate in combination with fluorouracil and cyclophosphamide as adjuvant chemotherapy for operable breast cancer: A study by the GEICAM group. Ann Oncol 2003;14:833-42.
10. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002;86:1041-6.
11. American Cancer Society. Breast cancer facts and figures2012. World Wide Web URL http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/ cancer-facts-figures-2012.
12. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18:581-92.
13. Chopra R. The Indian Scene. J Clin Oncol 2001;19 (18 suppl):106S-11S.
14. Murthy NS, Mathew A. Cancer epidemiology, prevention and control. Curr Sci 2004;86:518-27.
15. Burstein HJ, Harris JR, Morrow M. Malignant tumors of breast. In: DeVita VT Jr, Lawrence TS, Steven A, editors. DeVita, Hellman and Rosenberg's Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia: Lippincott Williams and Wilkins; 2008. p. 1606-54.
16. Dunnwald LK, Rossing MA, Li CI. Hormone receptor status, tumour characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res 2007;9:R6.
17. Huang WB, Zhou XJ, Chen JY, Zhang LH, Meng K, Ma HH, et al. CD10-positive stromal cells in gastric carcinoma: Correlation with invasion and metastasis. Jpn J Clin Oncol 2005;35:245-50.
18. Tse GM, Tsang AK, Putti TC, Scolyer RA, Lui PC, Law BK, et al. Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours. J Clin Pathol 2005;58:185-9.